These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

132 related items for PubMed ID: 3129393

  • 1. An open study of the safety and efficacy of enoxacin in complicated urinary tract infections.
    Foot M, Williams G, Want S, Roe M, Quaghebeur G, Bates S.
    J Antimicrob Chemother; 1988 Feb; 21 Suppl B():97-103. PubMed ID: 3129393
    [Abstract] [Full Text] [Related]

  • 2. Enoxacin: in-vitro and animal evaluation as a parenteral and oral agent against hospital bacterial isolates.
    Heifetz CL, Bien PA, Cohen MA, Dombrowski ME, Griffin TJ, Malta TE, Sesnie JC, Shapiro MA, Wold SA.
    J Antimicrob Chemother; 1988 Feb; 21 Suppl B():29-42. PubMed ID: 3129392
    [Abstract] [Full Text] [Related]

  • 3. Enoxacin treatment of urinary tract infections.
    Thomas MG, Ellis-Pegler RB.
    J Antimicrob Chemother; 1985 Jun; 15(6):759-63. PubMed ID: 3861605
    [Abstract] [Full Text] [Related]

  • 4. Enoxacin for the treatment of urinary tract infection.
    Bailey RR, Peddie BA.
    N Z Med J; 1985 Apr 24; 98(777):286-8. PubMed ID: 3857511
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Enoxacin in the treatment of lower respiratory tract infections.
    Philip-Joet F, Nourrit J, Frances Y, Arnaud A.
    J Antimicrob Chemother; 1988 Feb 24; 21 Suppl B():125-9. PubMed ID: 3258863
    [Abstract] [Full Text] [Related]

  • 11. [Comparison of fluoroquinolones (norfloxacin, enoxacin, ofloxacin) in the therapy of lower urinary tract infections].
    Tizzani A, Casetta G, Cavallini A, Piana P.
    Minerva Urol Nefrol; 1990 Feb 24; 42(2):81-4. PubMed ID: 2392745
    [Abstract] [Full Text] [Related]

  • 12. A random comparative trial of 0.25, 0.5 and 1.0 g ceftazidime twice daily in urinary tract infection.
    Gentry LO, Douthit MB, Childs SJ, Madsen PO.
    J Antimicrob Chemother; 1983 Jul 24; 12 Suppl A():53-7. PubMed ID: 6352655
    [Abstract] [Full Text] [Related]

  • 13. The correlation of sulfonamide disc sensitivity testing with the outcome of therapy in patients with urinary tract infections.
    Bauer AW.
    Chemotherapy; 1983 Jul 24; 10(3):152-63. PubMed ID: 4956134
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Enoxacin in lower respiratory tract infections.
    Wijnands WJ, van Griethuysen AJ, Vree TB, Van Klingeren B, van Herwaarden CL.
    J Antimicrob Chemother; 1986 Dec 24; 18(6):719-27. PubMed ID: 3469179
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Vibramycin in urinary tract infections].
    Oswald K.
    Med Klin; 1968 May 17; 63(20):804-6. PubMed ID: 4974095
    [No Abstract] [Full Text] [Related]

  • 18. The pharmacokinetics of enoxacin in elderly patients.
    Wise R, Baker SL, Misra M, Griggs D.
    J Antimicrob Chemother; 1987 Mar 17; 19(3):343-50. PubMed ID: 3471751
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans.
    Hooper DC, Wolfson JS.
    Antimicrob Agents Chemother; 1985 Nov 17; 28(5):716-21. PubMed ID: 2936302
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.